Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Bruker Corporation

BRKR

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Last trade $61.54
Day change +$0.915 (+1.51%)
Day range $60.09 – $62.06
Volume 862,800
Market cap $9.26B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$9.26B
Price / earnings
—
Price / book
4.01×
Price / sales
2.64×
EV / sales
3.09×
EV / EBITDA
23.18×

Profitability

Earnings per share
-$1.10
Return on assets
-2.87%
Return on equity
-7.25%
Dividend yield
0.79%

Liquidity and leverage

Debt / equity
0.74×
Current ratio
1.84×
Quick ratio
0.9×
Cash ratio
0.1×

Cash flow

Price / cash flow
27.09×
Price / free cash flow
43×
Free cash flow
$215.3M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BRKR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$874M$838.5M$823.4M$977.2M$860.5M$797.4M$801.4M$979.6M
Cost of revenue$444.7M$422.5M$443.6M$528M$481.1M$439.5M$410.2M$486.3M
Gross profit$429.3M$416M$379.8M$449.2M$379.4M$357.9M$391.2M$493.3M
Selling, general and administrative$226.5M$238.9M$242.1M$247.2M$242.5M$231.4M$225.4M$247.3M
Research and development$92M$94.3M$101.3M$99.6M$98.3M$100.2M$97.1M$104.4M
Total operating expenses$520.3M$481.3M$369.6M$372.9M$431.2M$346M$359.4M$421.2M
Operating income-$91M-$65.3M$10.2M$76.3M-$51.8M$11.9M$31.8M$72.1M
Interest expense-$15.4M-$17.8M$0$0-$20.3M-$15.7M$0$0
Income before taxes-$120.3M-$40.7M$21.9M$68.2M-$71.8M$500K$25.1M$56.1M
Income taxes-$12.2M$14.2M$2.5M$37.8M-$14.1M-$3.1M$8.7M$40.7M
Net income-$109.7M-$50.9M$15.7M$29.2M-$58.5M$4.2M$16.8M$13.9M
Net income attributable to common shareholders-$122.8M-$62.9M$3.5M$14.9M-$62.4M$7.6M$17.4M$13.7M
EBITDA$137.6M$127.6M$68.5M$134.4M$100.4M$68M$82.2M$125M
Basic earnings per share-$0.81-$0.41$0.02$0.10-$0.41$0.05$0.11$0.09
Diluted earnings per share-$0.81-$0.41$0.02$0.10-$0.41$0.05$0.11$0.09

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's Why Bruker (BRKR) is a Strong Momentum Stock

Bruker Corporation (BRKR), a life science and materials research systems manufacturer, is highlighted as a momentum investment opportunity despite holding a #3 (Hold) Zacks Rank. The stock has gained 9.5% over four weeks with positive earnings estimate revisions and a strong Momentum Style Score of A, though it carries a VGM Score of B.

Zacks Investment Research

Should You Continue to Retain Bruker Stock in Your Portfolio?

Bruker Corporation (BRKR) is well-positioned for growth driven by strong diagnostics and biosystems revenue, favorable European demand, and a $140 million cost-savings target by 2026 aimed at expanding margins by 250-300 basis points. However, uneven U.S. academic demand, macroeconomic uncertainty, and trade policy volatility present headwinds. The stock carries a Zacks Rank #3 (Hold) rating with a 3.4% earnings yield.

Zacks Investment Research

Bruker Gains 66.3% in a Year: What's Driving the Rally?

Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash.

Zacks Investment Research

Are Options Traders Betting on a Big Move in Bruker Stock?

Bruker Corporation (BRKR) is experiencing elevated implied volatility in its December 2026 $75 put options, suggesting traders expect significant price movement. However, the fundamental outlook remains weak, with analysts downgrading estimates over the past 60 days, pushing the consensus estimate down from 55 cents to 42 cents per share. The stock holds a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term

Bruker Corporation (BRKR), a life science and materials research systems manufacturer, is highlighted as a momentum investment opportunity despite holding a #3 (Hold) Zacks Rank. The stock has gained 4.3% over the past four weeks and features strong Momentum and VGM Style Scores of A and B respectively. One analyst raised earnings estimates for fiscal 2026, with the consensus estimate at $2.12 per share and an average earnings surprise of +22.7%.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Sep 21, 2026$0.05Oct 7, 2026recurring
Jun 22, 2026$0.05Jul 7, 2026recurring
Mar 23, 2026$0.05Apr 7, 2026recurring
Dec 8, 2025$0.05Jan 2, 2026recurring
Sep 23, 2025$0.05Oct 3, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.